ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients

O. A. Cornely, M. Bassetti, T. Calandra, J. Garbino, B. J. Kullberg, O. Lortholary, W. Meersseman, M. Akova, M. C. Arendrup, S. Arikan-Akdagli, J. Bille, E. Castagnola, M. Cuenca-Estrella, J. P. Donnelly, A. H. Groll, R. Herbrecht, W. W. Hope, H. E. Jensen, C. Lass-Flörl, G. PetrikkosM. D. Richardson, E. Roilides, P. E. Verweij, C. Viscoli, A. J. Ullmann

Research output: Contribution to journalArticle

Abstract

This part of the EFISG guidelines focuses on non-neutropenic adult patients. Only a few of the numerous recommendations can be summarized in the abstract. Prophylactic usage of fluconazole is supported in patients with recent abdominal surgery and recurrent gastrointestinal perforations or anastomotic leakages. Candida isolation from respiratory secretions alone should never prompt treatment. For the targeted initial treatment of candidaemia, echinocandins are strongly recommended while liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength. Treatment duration for candidaemia should be a minimum of 14days after the end of candidaemia, which can be determined by one blood culture per day until negativity. Switching to oral treatment after 10days of intravenous therapy has been safe in stable patients with susceptible Candida species. In candidaemia, removal of indwelling catheters is strongly recommended. If catheters cannot be removed, lipid-based amphotericin B or echinocandins should be preferred over azoles. Transoesophageal echocardiography and fundoscopy should be performed to detect organ involvement. Native valve endocarditis requires surgery within a week, while in prosthetic valve endocarditis, earlier surgery may be beneficial. The antifungal regimen of choice is liposomal amphotericin B+/-flucytosine. In ocular candidiasis, liposomal amphotericin B+/-flucytosine is recommended when the susceptibility of the isolate is unknown, and in susceptible isolates, fluconazole and voriconazole are alternatives. Amphotericin B deoxycholate is not recommended for any indication due to severe side effects.

Original languageEnglish
Pages (from-to)19-37
Number of pages19
JournalClinical Microbiology and Infection
Volume18
Issue numberSUPPL.7
DOIs
Publication statusPublished - Dec 2012

Keywords

  • Candidiasis
  • Guideline
  • Non-neutropenic
  • Prophylaxis
  • Treatment

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Medicine(all)

Fingerprint Dive into the research topics of 'ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients'. Together they form a unique fingerprint.

  • Cite this

    Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Castagnola, E., Cuenca-Estrella, M., Donnelly, J. P., Groll, A. H., Herbrecht, R., Hope, W. W., Jensen, H. E., Lass-Flörl, C., ... Ullmann, A. J. (2012). ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clinical Microbiology and Infection, 18(SUPPL.7), 19-37. https://doi.org/10.1111/1469-0691.12039